Key Points
- Director Martin Marino bought a total of 152,500 shares of Microbix in December (100,000 on Dec 22 at C$0.23 and 52,500 on Dec 29 at C$0.24), raising his holdings to 1,744,167 shares (a 3.10% increase).
- MBX trades near C$0.22 with a market cap of C$30.5M and a negative trailing EPS (C($0.01)), though analysts forecast about C$0.02 for the current fiscal year; the company also shows strong liquidity (quick ratio 5.57, current ratio 7.15).
Microbix Biosystems Inc. (TSE:MBX - Get Free Report) Director Martin Marino acquired 52,500 shares of Microbix Biosystems stock in a transaction that occurred on Monday, December 29th. The shares were purchased at an average cost of C$0.24 per share, with a total value of C$12,600.00. Following the completion of the acquisition, the director owned 1,744,167 shares of the company's stock, valued at C$418,600.08. The trade was a 3.10% increase in their position.
Martin Marino also recently made the following trade(s):
- On Monday, December 22nd, Martin Marino bought 100,000 shares of Microbix Biosystems stock. The stock was purchased at an average cost of C$0.23 per share, for a total transaction of C$23,000.00.
Microbix Biosystems Trading Up 2.3%
Shares of MBX stock opened at C$0.22 on Friday. The stock has a market cap of C$30.54 million, a P/E ratio of -13.75 and a beta of 0.03. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61. Microbix Biosystems Inc. has a fifty-two week low of C$0.21 and a fifty-two week high of C$0.55. The business has a fifty day simple moving average of C$0.24 and a 200-day simple moving average of C$0.25.
Microbix Biosystems (TSE:MBX - Get Free Report) last released its quarterly earnings data on Thursday, December 18th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$3.74 million during the quarter. Microbix Biosystems had a return on equity of 12.65% and a net margin of 13.86%. On average, analysts forecast that Microbix Biosystems Inc. will post 0.02 earnings per share for the current fiscal year.
Microbix Biosystems Company Profile
(
Get Free Report)
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
